Cyclophosphamide, mitoxantrone, fluorouracil versus conventional CMF as adjuvant treatment in node-positive breast cancer patients. A Hellenic Cooperative Oncology Group Study
Autor: | Fountzilas, G., Polichronis, A., Katsohis, K., Gennatas, K., Toussis, D., Skarlos, D., Kosmidis, P., Vassilaros, S., Semoglou, C., Giannakakis, T., Fahantidis, E., Klouvas, G., Tsavaris, N., Konstantaras, C., Makrantonakis, P., Kolotas, C., Zamboglou, N., Tsiliakos, S., Hainoglou, D., Mylonakis, N., Pavlidis, N. |
---|---|
Rok vydání: | 1996 |
Předmět: |
Adult
Cyclophosphamide/administration & dosage/adverse effects Breast Neoplasms/*drug therapy/mortality/pathology Fluorouracil/administration & dosage/adverse effects Remission Induction Breast Neoplasms Middle Aged Mitoxantrone/administration & dosage/adverse effects Survival Rate Methotrexate Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use Chemotherapy Adjuvant Antineoplastic Combined Chemotherapy Protocols Humans Female Fluorouracil Methotrexate/administration & dosage/adverse effects Mitoxantrone Cyclophosphamide Aged Follow-Up Studies |
Zdroj: | Oncology. 53(2) |
ISSN: | 0030-2414 |
Popis: | 362 evaluable node-positive patients with stage II breast cancer were randomized, receiving either 6 cycles of conventional CMF or 6 cycles of the combination of cyclophosphamide (500 mg/m2), mitoxantrone (Novantrone 10 mg/m2), and fluorouracil (500 mg/m2; CNF). After a median follow-up of 51 months, 64 (36%) patients relapsed in the CMF group and 60 (33%) in the CNF group (p=0.8276). By Cox multivariate analysis, tumor size, menopausal status and number of involved nodes were retained as independently significant variables. Toxicities were remarkably similar in both groups. It appears that after a median follow-up of 51 months there is no significant difference in relapse-free survival between node-positive patients with breast cancer who received either 6 cycles of the conventional CMF or the CNF combination as adjuvant treatment. Oncology |
Databáze: | OpenAIRE |
Externí odkaz: |